NeuroPace (NPCE) Competitors

$15.92 -0.07 (-0.41%)

As of 02:50 PM Eastern

NPCE vs. NVCR, ESTA, EYE, PRCT, and ENOV

Should you buy NeuroPace stock or one of its competitors? MarketBeat compares NeuroPace with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with NeuroPace include NovoCure (NVCR), Establishment Labs (ESTA), National Vision (EYE), PROCEPT BioRobotics (PRCT), and Enovis (ENOV). These companies are all part of the "medical equipment" industry.

How does NeuroPace compare to NovoCure?

NovoCure (NASDAQ:NVCR) and NeuroPace (NASDAQ:NPCE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

84.6% of NovoCure shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 5.5% of NovoCure shares are held by insiders. Comparatively, 20.5% of NeuroPace shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

NeuroPace has lower revenue, but higher earnings than NovoCure. NeuroPace is trading at a lower price-to-earnings ratio than NovoCure, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NovoCure	$655.35M	3.05	-$136.23M	-$1.53	N/A
NeuroPace	$99.99M	5.43	-$21.47M	-$0.65	N/A

NovoCure has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market.

NovoCure presently has a consensus target price of $27.29, suggesting a potential upside of 57.89%. NeuroPace has a consensus target price of $18.83, suggesting a potential upside of 18.26%. Given NovoCure's higher possible upside, research analysts clearly believe NovoCure is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NovoCure	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.38
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

NeuroPace has a net margin of -21.67% compared to NovoCure's net margin of -25.66%. NovoCure's return on equity of -50.82% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NovoCure	-25.66%	-50.82%	-16.48%
NeuroPace	-21.67%	-108.20%	-18.50%

In the previous week, NeuroPace had 18 more articles in the media than NovoCure. MarketBeat recorded 18 mentions for NeuroPace and 0 mentions for NovoCure. NovoCure's average media sentiment score of 1.45 beat NeuroPace's score of 0.65 indicating that NovoCure is being referred to more favorably in the media.

Company	Overall Sentiment
NovoCure	Positive
NeuroPace	Positive

Summary

NeuroPace beats NovoCure on 9 of the 16 factors compared between the two stocks.

How does NeuroPace compare to Establishment Labs?

Establishment Labs (NASDAQ:ESTA) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations and profitability.

Establishment Labs presently has a consensus price target of $87.14, suggesting a potential upside of 31.54%. NeuroPace has a consensus price target of $18.83, suggesting a potential upside of 18.26%. Given Establishment Labs' higher probable upside, research analysts plainly believe Establishment Labs is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Establishment Labs	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Establishment Labs has a beta of 1.12, meaning that its share price is 12% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, meaning that its share price is 92% more volatile than the broader market.

72.9% of Establishment Labs shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 10.0% of Establishment Labs shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Establishment Labs has a net margin of -19.05% compared to NeuroPace's net margin of -21.67%. NeuroPace's return on equity of -108.20% beat Establishment Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Establishment Labs	-19.05%	-218.77%	-12.31%
NeuroPace	-21.67%	-108.20%	-18.50%

In the previous week, NeuroPace had 13 more articles in the media than Establishment Labs. MarketBeat recorded 18 mentions for NeuroPace and 5 mentions for Establishment Labs. NeuroPace's average media sentiment score of 0.65 beat Establishment Labs' score of 0.19 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Establishment Labs	0 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroPace has lower revenue, but higher earnings than Establishment Labs. Establishment Labs is trading at a lower price-to-earnings ratio than NeuroPace, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Establishment Labs	$211.08M	9.24	-$51.06M	-$1.49	N/A
NeuroPace	$99.99M	5.43	-$21.47M	-$0.65	N/A

Summary

NeuroPace beats Establishment Labs on 11 of the 17 factors compared between the two stocks.

How does NeuroPace compare to National Vision?

NeuroPace (NASDAQ:NPCE) and National Vision (NASDAQ:EYE) are both small-cap medical equipment companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

National Vision has higher revenue and earnings than NeuroPace. NeuroPace is trading at a lower price-to-earnings ratio than National Vision, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NeuroPace	$99.99M	5.43	-$21.47M	-$0.65	N/A
National Vision	$1.99B	0.69	$29.60M	$0.57	29.93

NeuroPace presently has a consensus price target of $18.83, suggesting a potential upside of 18.26%. National Vision has a consensus price target of $30.08, suggesting a potential upside of 76.35%. Given National Vision's higher probable upside, analysts clearly believe National Vision is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
National Vision	0 Sell rating(s)	5 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.58

National Vision has a net margin of 2.31% compared to NeuroPace's net margin of -21.67%. National Vision's return on equity of 6.41% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NeuroPace	-21.67%	-108.20%	-18.50%
National Vision	2.31%	6.41%	2.81%

In the previous week, National Vision had 4 more articles in the media than NeuroPace. MarketBeat recorded 22 mentions for National Vision and 18 mentions for NeuroPace. National Vision's average media sentiment score of 0.75 beat NeuroPace's score of 0.65 indicating that National Vision is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
National Vision	8 Very Positive mention(s)	6 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

78.8% of NeuroPace shares are held by institutional investors. 20.5% of NeuroPace shares are held by company insiders. Comparatively, 2.4% of National Vision shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

NeuroPace has a beta of 1.92, suggesting that its stock price is 92% more volatile than the broader market. Comparatively, National Vision has a beta of 1.18, suggesting that its stock price is 18% more volatile than the broader market.

Summary

National Vision beats NeuroPace on 11 of the 17 factors compared between the two stocks.

How does NeuroPace compare to PROCEPT BioRobotics?

PROCEPT BioRobotics (NASDAQ:PRCT) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, analyst recommendations and earnings.

NeuroPace has a net margin of -21.67% compared to PROCEPT BioRobotics' net margin of -31.82%. PROCEPT BioRobotics' return on equity of -27.70% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PROCEPT BioRobotics	-31.82%	-27.70%	-20.29%
NeuroPace	-21.67%	-108.20%	-18.50%

PROCEPT BioRobotics has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, indicating that its stock price is 92% more volatile than the broader market.

89.5% of PROCEPT BioRobotics shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 6.6% of PROCEPT BioRobotics shares are owned by company insiders. Comparatively, 20.5% of NeuroPace shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

PROCEPT BioRobotics presently has a consensus target price of $41.45, suggesting a potential upside of 59.81%. NeuroPace has a consensus target price of $18.83, suggesting a potential upside of 18.26%. Given PROCEPT BioRobotics' higher possible upside, research analysts plainly believe PROCEPT BioRobotics is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PROCEPT BioRobotics	2 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.43
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

NeuroPace has lower revenue, but higher earnings than PROCEPT BioRobotics. NeuroPace is trading at a lower price-to-earnings ratio than PROCEPT BioRobotics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PROCEPT BioRobotics	$322.02M	4.58	-$95.57M	-$1.82	N/A
NeuroPace	$99.99M	5.43	-$21.47M	-$0.65	N/A

In the previous week, NeuroPace had 11 more articles in the media than PROCEPT BioRobotics. MarketBeat recorded 18 mentions for NeuroPace and 7 mentions for PROCEPT BioRobotics. PROCEPT BioRobotics' average media sentiment score of 0.77 beat NeuroPace's score of 0.65 indicating that PROCEPT BioRobotics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
PROCEPT BioRobotics	3 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

NeuroPace beats PROCEPT BioRobotics on 10 of the 17 factors compared between the two stocks.

How does NeuroPace compare to Enovis?

Enovis (NYSE:ENOV) and NeuroPace (NASDAQ:NPCE) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, institutional ownership, valuation, analyst recommendations, media sentiment, dividends, earnings and risk.

Enovis has a beta of 1.41, indicating that its share price is 41% more volatile than the broader market. Comparatively, NeuroPace has a beta of 1.92, indicating that its share price is 92% more volatile than the broader market.

Enovis currently has a consensus price target of $45.17, suggesting a potential upside of 76.34%. NeuroPace has a consensus price target of $18.83, suggesting a potential upside of 18.26%. Given Enovis' stronger consensus rating and higher possible upside, analysts clearly believe Enovis is more favorable than NeuroPace.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Enovis	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
NeuroPace	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

98.5% of Enovis shares are owned by institutional investors. Comparatively, 78.8% of NeuroPace shares are owned by institutional investors. 2.9% of Enovis shares are owned by insiders. Comparatively, 20.5% of NeuroPace shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, NeuroPace had 15 more articles in the media than Enovis. MarketBeat recorded 18 mentions for NeuroPace and 3 mentions for Enovis. NeuroPace's average media sentiment score of 0.65 beat Enovis' score of 0.59 indicating that NeuroPace is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Enovis	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
NeuroPace	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

NeuroPace has a net margin of -21.67% compared to Enovis' net margin of -49.92%. Enovis' return on equity of 10.32% beat NeuroPace's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Enovis	-49.92%	10.32%	4.57%
NeuroPace	-21.67%	-108.20%	-18.50%

NeuroPace has lower revenue, but higher earnings than Enovis. NeuroPace is trading at a lower price-to-earnings ratio than Enovis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Enovis	$2.25B	0.66	-$1.18B	-$19.88	N/A
NeuroPace	$99.99M	5.43	-$21.47M	-$0.65	N/A

Summary

NeuroPace beats Enovis on 9 of the 17 factors compared between the two stocks.

Get NeuroPace News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NPCE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NPCE vs. The Competition

Export

Metric	NeuroPace	MED INSTRUMENTS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$543.02M	$6.92B	$6.29B	$12.15B
Dividend Yield	N/A	1.75%	2.80%	5.32%
P/E Ratio	-24.51	49.44	20.64	25.14
Price / Sales	5.43	82.60	580.02	91.94
Price / Cash	N/A	24.43	27.48	37.30
Price / Book	27.94	6.61	9.75	6.65
Net Income	-$21.47M	$158.81M	$3.55B	$335.51M
7 Day Performance	0.79%	-0.79%	-1.59%	-1.56%
1 Month Performance	-1.64%	-5.16%	-3.51%	-1.44%
1 Year Performance	-6.32%	-3.94%	30.08%	28.08%

NeuroPace Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NPCE NeuroPace	3.5376 of 5 stars	$15.93 -0.4%	$18.83 +18.3%	-8.6%	$543.02M	$99.99M	N/A	170	Earnings Report Analyst Revision
NVCR NovoCure	3.6968 of 5 stars	$18.09 -0.1%	$27.29 +50.8%	-2.4%	$2.09B	$655.35M	N/A	1,605	Positive News
ESTA Establishment Labs	3.4853 of 5 stars	$68.37 -4.4%	$87.14 +27.5%	+81.5%	$2.01B	$211.08M	N/A	1,004
EYE National Vision	4.5248 of 5 stars	$21.30 -2.3%	$32.08 +50.6%	-9.9%	$1.71B	$1.99B	57.67	13,138	Earnings Report
PRCT PROCEPT BioRobotics	3.9658 of 5 stars	$28.05 +6.0%	$41.45 +47.8%	-55.2%	$1.60B	$308.05M	N/A	430	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NPCE) was last updated on 5/19/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

NeuroPace (NPCE) Competitors

NPCE vs. NVCR, ESTA, EYE, PRCT, and ENOV

How does NeuroPace compare to NovoCure?

Summary

How does NeuroPace compare to Establishment Labs?

Summary

How does NeuroPace compare to National Vision?

Summary

How does NeuroPace compare to PROCEPT BioRobotics?

Summary

How does NeuroPace compare to Enovis?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

NeuroPace (NPCE) Competitors

NPCE vs. NVCR, ESTA, EYE, PRCT, and ENOV

How does NeuroPace compare to NovoCure?

Do insiders and institutionals believe in NVCR or NPCE?

Which has preferable earnings & valuation, NVCR or NPCE?

Which has more volatility & risk, NVCR or NPCE?

Do analysts recommend NVCR or NPCE?

Is NVCR or NPCE more profitable?

Does the media favor NVCR or NPCE?

Summary

How does NeuroPace compare to Establishment Labs?

Do analysts prefer ESTA or NPCE?

Which has more risk & volatility, ESTA or NPCE?

Do insiders & institutionals believe in ESTA or NPCE?

Is ESTA or NPCE more profitable?

Does the media favor ESTA or NPCE?

Which has preferable valuation and earnings, ESTA or NPCE?

Summary

How does NeuroPace compare to National Vision?

Which has higher valuation and earnings, NPCE or EYE?

Do analysts rate NPCE or EYE?

Is NPCE or EYE more profitable?

Does the media prefer NPCE or EYE?

Do insiders and institutionals hold more shares of NPCE or EYE?

Which has more risk and volatility, NPCE or EYE?

Summary

How does NeuroPace compare to PROCEPT BioRobotics?

Is PRCT or NPCE more profitable?

Which has more volatility & risk, PRCT or NPCE?

Do insiders & institutionals hold more shares of PRCT or NPCE?

Do analysts recommend PRCT or NPCE?

Which has stronger valuation and earnings, PRCT or NPCE?

Does the media prefer PRCT or NPCE?

Summary

How does NeuroPace compare to Enovis?

Which has more risk and volatility, ENOV or NPCE?

Do analysts recommend ENOV or NPCE?

Do institutionals and insiders hold more shares of ENOV or NPCE?

Does the media favor ENOV or NPCE?

Is ENOV or NPCE more profitable?

Which has higher earnings & valuation, ENOV or NPCE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NPCE vs. The Competition

NeuroPace Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools